Harnessing a Bispecific Antibody That Selectively Depletes Tregs in the Tumor Microenvironment

Time: 4:30 pm
day: Day Two


  • Developing a bispecific antibody that binds specifically to tumor-localized Tregs resulting in Treg depletion in tumors
  • Optimizing geometry and affinity of the bispecific antibody to maximize tumor Treg specificity
  • Presenting preclinical data and efficacy profiles in mice, and overcoming manufacturing hurdles to progress to the clinic